Company: CERO
Filing Date: 2025-01-23
Form Type: 424B3
Source: 0001213900-25-005624
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-23
Form: 424B3
Chunk 2
---
12(b) of the Act:

| Title of each class                                                    |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share                              |     | CERO              |     | NASDAQ Global Market                      |
| Warrants, each whole warrant exercisable for one share of common stock |     | CEROW             |     | NASDAQ Capital Market                     |

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 17, 2025, CERo
Therapeutics Holdings, Inc. (the “Company”) received a letter setting forth the determination of a panel convened by Nasdaq
(the “Nasdaq Panel”) granting the Company’s request for an extension (the “Extension”) to regain compliance
with certain continued listing requirements of the Nasdaq Stock Market until April 22, 2025 (the “Extension Date”). The Company
presented its plan (the “Plan”) for regaining compliance with such requirements at a hearing conducted on December 17, 2025.

As previously disclosed, the
Company has not been in compliance with the $50 million minimum Market Value of Listed Securities requirement (the “MVLS Requirement”),
the $15 million minimum Market Value of Publicly Held Securities requirement (the “MVPHS Requirement”) and the $1.00 minimum
Bid Price requirement (the “Bid Price Requirement”). All applicable automatic grace periods for regaining compliance for such
requirements have expired. The Company’s Plan includes transferring the listing of its securities to the Nasdaq Capital Market,
which permits companies to satisfy a $2.5 million minimum stockholders’ equity requirement in lieu of the MVLS Requirement, and
a lower $1 million MVPHS Requirement, completing a reverse stock split to regain compliance with the Bid Price Requirement and certain
capital raising activities to attain such $2.5 million of stockholders’ equity.

The Extension is subject
to certain conditions, including that the